Headlines about C R Bard (NYSE:BCR) have been trending somewhat positive on Sunday, according to Accern. Accern ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. C R Bard earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 47.440269715879 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
NYSE BCR remained flat at $$331.24 during trading hours on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. C R Bard has a 12 month low of $222.42 and a 12 month high of $337.73.
Separately, Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price for the company in a research report on Tuesday, December 26th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. C R Bard presently has an average rating of “Hold” and an average target price of $320.83.
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.